文献速递贫血与红细胞疾病白血病淋巴瘤

血液系统恶性肿瘤患者感染COVID-19:中国最新奥密克戎浪潮中的单中心调查

COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
PubMed 文献 · Br J Haematol · 2023-04-24

该单中心调查纳入412例血液系统恶性肿瘤合并COVID-19患者,观察到10.4%发生COVID-19肺炎、5.3%为重型/危重型。晚期恶性肿瘤患者重型/危重型COVID-19发生率17.6%、死亡率10.5%、30天总生存74.2%,均显著劣于稳定恶性肿瘤患者。多因素分析显示年龄超过65岁、合并症和晚期恶性肿瘤与重型/危重型COVID-19相关。

要点

  • 412例血液系统恶性肿瘤合并COVID-19患者中,COVID-19肺炎占10.4%,重型/危重型占5.3%。
  • 晚期恶性肿瘤患者重型/危重型COVID-19发生率为17.6%,显著高于稳定恶性肿瘤患者的2.70%。
  • 晚期恶性肿瘤患者死亡率10.5%、30天总生存74.2%,均显著劣于稳定恶性肿瘤患者。

核心结论

  • 血液系统恶性肿瘤合并COVID-19患者中,晚期恶性肿瘤是重型/危重型COVID-19和死亡的主要相关因素。

研究设计与样本

  • 单中心调查,纳入412例血液系统恶性肿瘤合并COVID-19患者,主要包含急性白血病、慢性髓性白血病、浆细胞疾病、淋巴瘤和慢性淋巴细胞白血病。

主要发现

  • COVID-19肺炎发生率为10.4%(43/412),重型/危重型为5.3%(22/412)。
  • 晚期恶性肿瘤患者重型/危重型COVID-19发生率为17.6%(12/86),稳定恶性肿瘤患者为2.70%(9/326),差异有统计学意义(p < 0.001)。
  • 晚期恶性肿瘤患者死亡率为10.5%(9/86),稳定恶性肿瘤患者为0%(0/326),差异有统计学意义(p < 0.001)。
  • 晚期恶性肿瘤患者30天总生存为74.2%,稳定恶性肿瘤患者为100.0%,差异有统计学意义(p < 0.0001)。
  • 共9例患者(2.2%)死亡,主要死因为血液系统恶性肿瘤进展(4例)以及COVID-19与血液系统恶性肿瘤共同导致(5例)。

关键数值与推荐

  • 多因素分析显示,年龄超过65岁、合并症和晚期恶性肿瘤与血液系统恶性肿瘤患者发生重型/危重型COVID-19相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the COVID-19 variant Omicron surge in Beijing, China, a better understanding of risk factors for adverse outcomes may improve clinical management in patients with haematological malignancies (HM) diagnosed with COVID-19. The study sample includes 412 cases, mainly represented by acute leukaemia, chronic myeloid leukaemia (CML), plasma cell disorders and lymphoma and chronic lymphocytic leukaemia. COVID-19 pneumonia was observed in 10.4% (43/412) of patients, and severe/critical illness was observed in 5.3% (22/412). Among the 86 cases with advanced malignancies, 17.6% (12/86) of patients developed severe/critical COVID-19, which was significantly higher than reported in patients with stable malignancies (9/326, 2.70%, p < 0.001). Similarly, the advanced malignancy cohort had a higher mortality rate (9/86, 10.5% vs. 0/326, 0%, p < 0.001) and a poor 30-day overall survival (OS) compared with the stable malignancy cohort (74.2% vs. 100.0%, p < 0.0001). Overall, nine patients (2.2%) died. The primary cause of death was progressive HM in four patients and a combination of both COVID-19 and HM in five patients. In the multivariable analysis, over 65 years of age, comorbidities and advanced malignancy were correlated with severe/critical COVID-19 in HM patients. This study sheds light on the poor outcomes among COVID-19 HM patients with the leading cause of advanced malignancy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhu X, Jiang Q, Lu J, et al. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China. Br J Haematol. 2023. PMID: 37092433. doi:10.1111/bjh.18823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。